Sean Corcoran

Sean Corcoran earned his BS in Biology from the Massachusetts Institute of Technology in 2016. During his undergraduate years, he worked on engineering novel uses for CRISPR/Cas9 in Rudolf Jaenisch's lab at the Whitehead Institute. After graduating, he moved to the beta-hemoglobinopathies team at CRISPR Therapeutics where he worked on cures for beta-thalassemia and sickle cell disease.

He began his MD/PhD degree at the Boston University School of Medicine in 2017 and transitioned in 2019 to the labs of Louis Staudt at the NCI and Daniel Hodson at Cambridge to complete his PhD. During his PhD he studied the B-cell receptor in Diffuse Large B-cell Lymphoma. He is expected to graduate from his PhD in 2023 and his MD in 2025 after which he will pursue a career as a physician scientist.